Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats

Chirality

Volumn 19, Issue 3, 2007, Pages 190-196

  Parasrampuria, Ridhi ^a   Vuppugalla, Ragini ^a   Elliott, Katherine ^a   Mehvar, Reza ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Chiral analysis; Enantioselective disposition; Extrahepatic metabolism; Gastrointestinal availability; Hepatic availability; Hepatic clearance; Metabolite kinetics; Oral bioavailability

Indexed keywords

DRUG METABOLITE; TRAMADOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHIRAL CHROMATOGRAPHY; DEMETHYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ENANTIOMER; GASTROINTESTINAL TRACT; LIVER BLOOD FLOW; LIVER METABOLISM; MALE; MEAN RESIDENCE TIME; NONCOMPARTMENTAL METHOD; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; TECHNIQUE; URINE;

ANALGESICS, OPIOID; ANIMALS; GASTROINTESTINAL TRACT; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TRAMADOL;

EID: 33847195072     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20360     Document Type: Article

References (23)

1. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-340.
2. Lintz W, Erlacin S, Frankus E, Uragg H. Biotransformation of tramadol in man and animal. Arzneimittelforschung 1981;31:1932-1943 (in German).
3. Wu WN, McKown LA, Liao S. Metabolism of the analgesic drug ULTRAM® (Tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 2002;32:411-425.
4. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988;38:877-880.
5. Valle M, Garrido MJ, Pavon JM, Calvo R, Troconiz IF. Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O- desmethyltramadol, in rats. J Pharmacol Exp Ther 2000;293:646-653.
6. Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human μ-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-121.
7. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923.
8. Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006;62:513-521.
9. Grand S, Meuser T, Uragg H, Stahlberg HJ, Lehmann KA. Serum concentrations of tramadol enantiomers during patient-controlled analgesia. Br J Clin Pharmacol 1999;48:254-257.
10. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 2005;77:312-323.
11. Ceccato A, Vanderbist F, Pabst JY, Streel B. Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;748:65-76.
12. Campanero MA, Calahorra B, Valle M, Troconiz IF, Honorato J. Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. Chirality 1999;11:272-279.
13. Liu HC, Liu TJ, Yang YY, Hou YN. Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. Acta Pharmacol Sin 2001;22:91-96.
14. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Investig 1992;70:708-710.
15. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, Liao S, Spielberg SP, Kearns GL. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002;42:24-29.
16. Garrido MJ, Valle M, Campanero MA, Calvo R, Troconiz IF. Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats. J Pharmacol Exp Ther 2000;295:352-359.
17. Garrido MJ, Sayar O, Segura C, Rapado J, DiosVieitez MC, Renedo MJ, Troconiz IF. Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. J Pharmacol Exp Ther 2003;305:710-718.
18. Liu HC, Jin SM, Wang YL. Gender-related differences in pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in rats. Acta Pharmacol Sin 2003;24:1265-1269.
19. Liu HC, Wang N, Liu CS, Hu YQ, Liu JF, Hou YN. Distribution of enantiomers of trans-tramadol and trans-O-demethyltramadol in central nervous system of rats. Acta Pharmacol Sin 2001;22:871-875.
20. Liu HC, Zhang XJ, Yang YY, Wang N, Hou YN. Stereo selectivity in renal clearance of trans-tramadol and its active metabolite, trans-O-demethyltramadol. Acta Pharmacol Sin 2002;23:83-86.
21. Pang KS. A review of metabolite kinetics. J Pharmacokinet Biopharm 1985;13:633-662.
22. Mehvar R. Apparent stereoselectivity in propafenone uptake by human and rat erythrocytes. Biopharm Drug Dispos 1991;12:299-310.
23. Harashima H, Sawada Y, Sugiyama Y, Iga T, Hanano M. Analysis of non-linear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. J Pharmacokinet Biopharm 1985;13:425-440.